A “skinny label” is one way that a generic drug can be commercialized in the US when only a subset of the brand’s uses lose exclusivity. The recent Supreme Court decision in the Caraco case may put a spotlight on the opportunities for “skinny label” generics. The article found here describes some of the issues and possible policy implications that may be associated with an increased use of “skinny labels.”
Funding innovation under pressure: examining the role of commercial health insurance in Europe
Europe’s health systems are facing growing pressure amidst strained public budgets, ageing populations, and increasing treatment costs, prompting urgent questio